Baird Raises Humana (HUM) Price Target to $596

Baird raises its rating for Humana Inc. to Outperform and sets a new price target of $596, a 42.46% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 2:08 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Baird raised its price target on Humana Inc. ($HUM) to $596 from $390 on October 9, 2026, and rates the stock "Outperform".

Since the rating, $HUM is down 4.3% after 1 week and down 4.3% to date (from the $431.87 close on Oct 9, 2026).

HUM Humana Inc.

$413.16 +57.38% year to date

Daily close · Oct 16, 2026

Key Points

On October 9, 2026, Baird upgraded Humana Inc. to an Outperform rating and raised its price target from $390 to $596.
Baird's $596 price target implies 42.46% upside from Humana Inc.'s ($HUM) current $418.36 share price.
As of October 16, 2026, Humana's shares recently traded around $418.36, which is about 10.1% below the mean analyst target of $465.13.
Humana Inc. has a market cap of approximately $51.9 billion and reported a revenue growth of 26.2% year-over-year.

Get $HUM trade alerts by text

We text you when insiders, Congress or big funds trade $HUM. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Humana Inc. alert may contain errors. Disclosures

Baird upgraded Humana Inc. (NYSE: HUM) to an Outperform rating on October 9, 2026. The firm raised its price target from $390 to $596, signaling increased confidence in the company's future performance. This upgrade comes as Humana has been showing strong growth metrics in the healthcare sector.

Other Institutional Activity in Humana Inc.

Dodge & Cox Inc. trimmed its holdings by 440,438 shares, ending with 10,940,380 shares valued at about $4.5 billion. Blackrock Inc. added 218,270 shares, bringing its total to 10,417,803 shares worth around $4.3 billion. Vanguard Capital Management LLC increased its position by 4,703 shares, totaling 7,843,620 shares valued at roughly $3.2 billion. Vanguard Portfolio Management LLC grew its stake by 10,455 shares, reaching 5,818,956 shares worth about $2.4 billion, while State Street Corporation slightly added 3,817 shares, holding 5,457,072 shares valued at approximately $2.3 billion.

Humana Inc. Stock Down 2.1%

Humana's shares recently traded around $418.36 as of October 16, 2026, which is 6.5% above its 50-day moving average of $393.00 and 39.3% above its 200-day moving average of $300.29. However, the stock is about 10.1% below the mean analyst target of $465.13, suggesting potential upside based on recent analyst upgrades.

12-month forecast

$HUM price target

Humana Inc. daily closes and this analyst's $596 target. Not advice.

Recent Earnings

In its latest earnings report, Humana reported a trailing twelve-month revenue of approximately $145.7 billion and an EPS of $10.88. The company is expected to announce its next earnings on November 6, 2026.

Insider Buying and Selling at Humana Inc.

On February 23, 2026, Officer Sanjay K. Shetty purchased 810 shares at an average price of $185.20, totaling about $150,016. This transaction occurred before Baird's recent upgrades.

Analysts Set New Price Targets

On the same day as Baird's upgrade, Barclays maintained an Overweight rating with a new target of $582, up from $515. Oppenheimer also maintained an Outperform rating, raising its target from $405 to $475. UBS later maintained a Neutral rating with a target increase to $495, while Truist Securities kept its Hold rating with a target rise to $475.

About Humana Inc.

Humana Inc. provides medical and specialty insurance products in the United States, operating in two segments: Insurance and CenterWell. The company's focus on healthcare plans positions it well in a growing market, especially as it continues to show strong financial performance.

Bottom Line

Investors should keep an eye on Humana's upcoming earnings report on November 6, 2026, and watch for further analyst ratings and price target adjustments following Baird's upgrade. With a strong growth trajectory and recent analyst confidence, Humana remains a company to watch in the healthcare sector.